Similar companies
Related EMIS Industry Reports
Jiangsu Deyuan Pharmaceutical Co., Ltd. is mainly engaged in the research and development, production and sales of tablets, hard capsules and APIs, and its main products include Ruitong (pioglitazone hydrochloride tablets), Tangrui (nateglinide tablets), Furuitong (pioglitazone metformin tablets), Bokaiqing (candihydrothiazine tablets), metformin hydrochloride sustained-release tablets, methylcobalamin capsules, pioglitazone hydrochloride, nateglinide APIs, etc. The company's products are mainly used in the treatment of diabetes, hypertension and peripheral neuropathy. According to the sales data of sample hospitals in key cities of the Pharmaceutical Association, in 2019, the top 5 pioglitazone sales in China are "Acto" of Takeda Pharmaceutical Industry Co., Ltd. of Japan, "Ruitong" of Deyuan Pharmaceutical, "Aitin" of Beijing Taiyang Pharmaceutical Co., Ltd., "Caspine" of Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., and "Beitangning" of Sichuan Luye Pharmaceutical Co., Ltd. occupy 88.98% of the share. Among them, Deyuan Pharmaceutical's market share is 19.54%.
Headquarters
No. 29, Changjiang Road, Economic and Technological Development Zone, Lianyungang City, Jiangsu Province
Lianyungang; Jiangsu;
Postal Code: 222047
Contact Details: Purchase the Jiangsu Deyuan Pharmaceutical Co., Ltd. report to view the information.
Website: http://www.pharmdy.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS service
To view more information, Request a demonstration of the EMIS service